HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.

Descripción del Articulo

Desde el estudio HannaH fase 3 aleatorizado, se reporta la asociación entre la respuesta total patológica completa y la supervivencia libre de eventos en el cáncer de mama HER2-positivo temprano, tratado con trastuzumab adyuvante-neoadyuvante de dosis fija, con más eficacia y seguridad a largo plazo...

Descripción completa

Detalles Bibliográficos
Autores: Jackisch, Christian, Hegg, Roberto, Stroyakovskiy, Daniil, Jin-Seok Ahn, Melichar, Bohuslav, Shin-Cheh Chen, Sung-Bae Kim, Lichinitser, Mikhail, Starosławska, Elzbieta, Kunz, Georg, Falcón, Silvia, Shou-Tung Chen, Crepelle-Fléchais, Aulde, Heinzmann, Dominik, Shing, Mona, Pivot, Xavier
Formato: artículo
Fecha de Publicación:2016
Institución:Seguro Social de Salud
Repositorio:ESSALUD-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.essalud.gob.pe:20.500.12959/202
Enlace del recurso:https://hdl.handle.net/20.500.12959/202
Nivel de acceso:acceso abierto
Materia:Oncología
Farmacología y Farmacia
Neoplasias de la mama
Trastuzumab
https://purl.org/pe-repo/ocde/ford#3.05.00
id ESSA_f1b956ce4fba3af9a822d0c8bf91144d
oai_identifier_str oai:repositorio.essalud.gob.pe:20.500.12959/202
network_acronym_str ESSA
network_name_str ESSALUD-Institucional
repository_id_str 4277
dc.title.es_PE.fl_str_mv HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
title HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
spellingShingle HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
Jackisch, Christian
Oncología
Farmacología y Farmacia
Neoplasias de la mama
Trastuzumab
https://purl.org/pe-repo/ocde/ford#3.05.00
title_short HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
title_full HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
title_fullStr HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
title_full_unstemmed HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
title_sort HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
author Jackisch, Christian
author_facet Jackisch, Christian
Hegg, Roberto
Stroyakovskiy, Daniil
Jin-Seok Ahn
Melichar, Bohuslav
Shin-Cheh Chen
Sung-Bae Kim
Lichinitser, Mikhail
Starosławska, Elzbieta
Kunz, Georg
Falcón, Silvia
Shou-Tung Chen
Crepelle-Fléchais, Aulde
Heinzmann, Dominik
Shing, Mona
Pivot, Xavier
author_role author
author2 Hegg, Roberto
Stroyakovskiy, Daniil
Jin-Seok Ahn
Melichar, Bohuslav
Shin-Cheh Chen
Sung-Bae Kim
Lichinitser, Mikhail
Starosławska, Elzbieta
Kunz, Georg
Falcón, Silvia
Shou-Tung Chen
Crepelle-Fléchais, Aulde
Heinzmann, Dominik
Shing, Mona
Pivot, Xavier
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Jackisch, Christian
Hegg, Roberto
Stroyakovskiy, Daniil
Jin-Seok Ahn
Melichar, Bohuslav
Shin-Cheh Chen
Sung-Bae Kim
Lichinitser, Mikhail
Starosławska, Elzbieta
Kunz, Georg
Falcón, Silvia
Shou-Tung Chen
Crepelle-Fléchais, Aulde
Heinzmann, Dominik
Shing, Mona
Pivot, Xavier
dc.subject.es_PE.fl_str_mv Oncología
Farmacología y Farmacia
Neoplasias de la mama
Trastuzumab
topic Oncología
Farmacología y Farmacia
Neoplasias de la mama
Trastuzumab
https://purl.org/pe-repo/ocde/ford#3.05.00
dc.subject.ocde.es_PE.fl_str_mv https://purl.org/pe-repo/ocde/ford#3.05.00
description Desde el estudio HannaH fase 3 aleatorizado, se reporta la asociación entre la respuesta total patológica completa y la supervivencia libre de eventos en el cáncer de mama HER2-positivo temprano, tratado con trastuzumab adyuvante-neoadyuvante de dosis fija, con más eficacia y seguridad a largo plazo.
publishDate 2016
dc.date.accessioned.none.fl_str_mv 2019-04-10T16:46:39Z
dc.date.available.none.fl_str_mv 2019-04-10T16:46:39Z
dc.date.issued.fl_str_mv 2016-05
dc.type.es_PE.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.citation.es_PE.fl_str_mv European Journal of Cancer
dc.identifier.issn.none.fl_str_mv 0959-8049
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12959/202
identifier_str_mv European Journal of Cancer
0959-8049
url https://hdl.handle.net/20.500.12959/202
dc.language.iso.es_PE.fl_str_mv eng
language eng
dc.rights.es_PE.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.es_PE.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.format.es_PE.fl_str_mv application/pdf
dc.publisher.es_PE.fl_str_mv Seguro Social de Salud (EsSalud)
dc.publisher.country.es_PE.fl_str_mv PE
dc.source.es_PE.fl_str_mv Seguro Social de Salud (EsSalud)
Repositorio Institucional EsSalud
dc.source.none.fl_str_mv reponame:ESSALUD-Institucional
instname:Seguro Social de Salud
instacron:ESSALUD
instname_str Seguro Social de Salud
instacron_str ESSALUD
institution ESSALUD
reponame_str ESSALUD-Institucional
collection ESSALUD-Institucional
bitstream.url.fl_str_mv https://repositorio.essalud.gob.pe/bitstream/20.500.12959/202/1/HannaH%20phase%20III%20randomised%20study%20Association%20of%20total%20pathological%20complete%20response%20with%20event-free%20survival%20in%20HER2-positive%20early%20breast%20cancer%20treated%20with%20neoadjuvant-adjuvant%20trastuzumab%20after%202%20years%20of%20tr.pdf
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/202/2/license.txt
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/202/3/HannaH%20phase%20III%20randomised%20study%20Association%20of%20total%20pathological%20complete%20response%20with%20event-free%20survival%20in%20HER2-positive%20early%20breast%20cancer%20treated%20with%20neoadjuvant-adjuvant%20trastuzumab%20after%202%20years%20of%20tr.pdf.txt
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/202/4/HannaH%20phase%20III%20randomised%20study%20Association%20of%20total%20pathological%20complete%20response%20with%20event-free%20survival%20in%20HER2-positive%20early%20breast%20cancer%20treated%20with%20neoadjuvant-adjuvant%20trastuzumab%20after%202%20years%20of%20tr.pdf.jpg
bitstream.checksum.fl_str_mv fc710607d03df91ef6acc6b81a20934f
8a4605be74aa9ea9d79846c1fba20a33
5082394f6f43bf02d25048364ba3d264
65b04968afa6a39e9ca13c8dd86d37f0
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Seguro Social de Salud – ESSALUD
repository.mail.fl_str_mv bibliotecacentral@essalud.gob.pe
_version_ 1813537121481261056
spelling Jackisch, ChristianHegg, RobertoStroyakovskiy, DaniilJin-Seok AhnMelichar, BohuslavShin-Cheh ChenSung-Bae KimLichinitser, MikhailStarosławska, ElzbietaKunz, GeorgFalcón, SilviaShou-Tung ChenCrepelle-Fléchais, AuldeHeinzmann, DominikShing, MonaPivot, Xavier2019-04-10T16:46:39Z2019-04-10T16:46:39Z2016-05European Journal of Cancer0959-8049https://hdl.handle.net/20.500.12959/202Desde el estudio HannaH fase 3 aleatorizado, se reporta la asociación entre la respuesta total patológica completa y la supervivencia libre de eventos en el cáncer de mama HER2-positivo temprano, tratado con trastuzumab adyuvante-neoadyuvante de dosis fija, con más eficacia y seguridad a largo plazo.application/pdfengSeguro Social de Salud (EsSalud)PEinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/4.0/Seguro Social de Salud (EsSalud)Repositorio Institucional EsSaludreponame:ESSALUD-Institucionalinstname:Seguro Social de Saludinstacron:ESSALUDOncologíaFarmacología y FarmaciaNeoplasias de la mamaTrastuzumabhttps://purl.org/pe-repo/ocde/ford#3.05.00HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.info:eu-repo/semantics/articleORIGINALHannaH phase III randomised study Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of tr.pdfHannaH phase III randomised study Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of tr.pdfapplication/pdf800846https://repositorio.essalud.gob.pe/bitstream/20.500.12959/202/1/HannaH%20phase%20III%20randomised%20study%20Association%20of%20total%20pathological%20complete%20response%20with%20event-free%20survival%20in%20HER2-positive%20early%20breast%20cancer%20treated%20with%20neoadjuvant-adjuvant%20trastuzumab%20after%202%20years%20of%20tr.pdffc710607d03df91ef6acc6b81a20934fMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.essalud.gob.pe/bitstream/20.500.12959/202/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52TEXTHannaH phase III randomised study Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of tr.pdf.txtHannaH phase III randomised study Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of tr.pdf.txtExtracted texttext/plain48952https://repositorio.essalud.gob.pe/bitstream/20.500.12959/202/3/HannaH%20phase%20III%20randomised%20study%20Association%20of%20total%20pathological%20complete%20response%20with%20event-free%20survival%20in%20HER2-positive%20early%20breast%20cancer%20treated%20with%20neoadjuvant-adjuvant%20trastuzumab%20after%202%20years%20of%20tr.pdf.txt5082394f6f43bf02d25048364ba3d264MD53THUMBNAILHannaH phase III randomised study Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of tr.pdf.jpgHannaH phase III randomised study Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of tr.pdf.jpgGenerated Thumbnailimage/jpeg7283https://repositorio.essalud.gob.pe/bitstream/20.500.12959/202/4/HannaH%20phase%20III%20randomised%20study%20Association%20of%20total%20pathological%20complete%20response%20with%20event-free%20survival%20in%20HER2-positive%20early%20breast%20cancer%20treated%20with%20neoadjuvant-adjuvant%20trastuzumab%20after%202%20years%20of%20tr.pdf.jpg65b04968afa6a39e9ca13c8dd86d37f0MD5420.500.12959/202oai:repositorio.essalud.gob.pe:20.500.12959/2022022-09-09 03:01:56.205Repositorio Seguro Social de Salud – ESSALUDbibliotecacentral@essalud.gob.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
score 13.932913
HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares